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Figure 1. Summarized scheme of the signaling pathway in TSC. In this 
disorder, the lack of a functional TSC1/2 complex leads to mTORC1 
hyperactivation, culminating in uncontrolled cell growth and proliferation, 
as well as aberrant synapses. 
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Figure 2. Initially (1), the Tsc1 gene is flanked by loxP sites and the cre 
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“pacman”). Tamoxifen administration (2), a potent ligand of the ER, 
induces the translocation of the ER-cre complex to the nucleus (3), 
where the cre recombinase recombines the loxP sites, resulting in Tsc1 
gene deletion. If tamoxifen is not administered, or the mouse does not 
express the cre recombinase, the mouse remains similar to WT, i.e, 
Tsc1+/+. 
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Figure 3. The EEG surgical procedure takes place with the mouse 
deeply anesthetized (1). An incision is made in the skin and fascia 
overlying the skull (2). Stainless steel screws (a) are used as EEG 
electrodes (3) and implanted in the skull at the approximate coordinates 
shown in b. In the end, the other end of the electrodes is plugged in a 
connector (highlighted in orange) and covered with dental cement (4). 
Scheme in (b) is adapted from George Paxinos and Keith Franklin: The 
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Mouse Brain in Stereotaxic Coordinates, Academic Press, 2001. 
Figure 4. Tsc1f/f mice were crossed with the cre line carrying the 
αCaMKII promoter until the Tsc1f/f-αCaMKII-erT2-cre construct, with cre+ 
and cre- littermates, was obtained. 
43 
Figure 5. PCR for Tsc1 using different brain areas and liver of Tsc1-
αCaMKII mice. Only cre+ tamoxifen injected mice show partial deletion 
in cortex and hippocampus. f: floxed band; -: deletion band 
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Figure 6. TSC1 and pS6/S6 levels in αCaMKII-positive brain regions of 
Tsc1-αCaMKII mice that underwent Tsc1 deletion: hippocampus (Hc), 
cortex (Ct) and cerebellum (Cb). All protein levels were normalized to 
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However, only hippocampus and cortex show mTORC1 hyperactivation 
(increased pS6/S6 levels). n=2 per group (preliminary data). 
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Figure 7. Sagital sections (5 x magnification) of a control (left) and a 
mutant Tsc1-αCaMKII mouse brain stained with an antibody against 
pS6. pS6-positive cells are highly present in cortex and hippocampus of 
the mutant Tsc1-αCaMKII mouse, while no differences are found in 
cerebellum. n=4 per group. 
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Figure 8. pS6-positive cells (red) highly co-localize with αCaMKII-
positive cells (green) in cortex (A, 10x; B, 20x) and hippocampus (C, 5x, 
D, 20x dentate gyrus, E, 20x CA3 region) of Tsc1-αCaMKII mice. n=5. 
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Figure 9. pS6-positive cells (red) do not co-localize with PV-positive 
cells (green) in cortex (A, 10x; B, 20x) and hippocampus (C, 5x, D, 20x 
dentate gyrus, E, 20x CA3 region) of Tsc1-αCaMKII mice. 
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Figure 10. Adopted protocol to assess epilepsy in Tsc1-αCaMKII mice 
through EEG recordings. After the EEG surgical procedure the mice are 
given a minimum of two days of rest. Then, two vehicle injections are 
administered and baseline measurements are acquired. After one day of 
rest, gene deletion is induced by tamoxifen administration and EEG 
measurements are acquired every night. 
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Figure 11. Examples of the observed types of recordings (A, baseline 
measurement; B, increased activity; C, seizure; D, lethal seizure) and 
the wireless neurologger device 
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Figure 12. The epilepsy onset of tamoxifen-injected cre+ mice varies 
between 9 and 12 days after the first tamoxifen injection in adulthood. 
Tamoxifen-injected cre- mice don’t show epilepsy. n=10. 
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Figure 13. Lifespan of tamoxifen-injected cre+ mice varies between 12 
and 16 days after the first tamoxifen injection in adulthood. Tamoxifen-
injected cre- mice don’t show decreased lifespan. n=4. 
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Figure 14. Number (per 16h of recording; upper graph) and length of 
seizures (in seconds; lower graph) of the recorded mice. Each color 
represents one mouse. n=3. 
52 
Figure 15. TSC1, TSC2, pS6/S6 and pAkt/Akt levels in control mice (c; 
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cre- tamoxifen-injected) and mutant mice (tamoxifen injected cre+) at 
day 8 (8; pre-epileptic state) and day 13 (13; epileptic state). Significant 
differences are shown by * (p=0.01, 1-way ANOVA), n=4 per group. 
Figure 16. NR1, NR2A and NR2B NMDA subunits and GluR1 AMPA 
subunit levels in hippocampal total lysates of control (c) and mutant mice 
at day 8 (8) or day 13 (13). n=4 per group, no significant differences 
were found (preliminary data). 
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Figure 17. NR2B, NR2A and NR1 NMDA subunits and GABAARα1 
subunit levels in cortical synaptosomes of control (c) and mutant mice at 
day 8 (8) and day 13 (13). n=4 per group, no significant differences were 
found (preliminary data). 
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Figure 18 No differences in gross brain morphology are observed in the 
hippocampus of Tsc1-αCaMKII mice (control on the left, mutant on the 
right). (All perfused brains were screened and no changes were found.) 
63 
Figure 19 No pS6-stained giant cells are found in the cortex of Tsc1-
αCaMKII epileptic mice (10 x magnification on the left, 40 x 
magnification on the right). 
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Figure 20. AZD8055 (10 mg/kg) is able to downregulate mTORC1 
(pS6/S6 levels) and mTORC2 (pAkt/Akt levels) in the hippocampus of 
WT mice. n=2 per group (preliminary data). 
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Figure 21. The effect of GD124 on mTORC1 and mTORC2 in the 
hippocampus of WT mice is inconclusive. n=2 per group (preliminary 
66 
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data). 
Figure 22. Number (per 16h of recording; upper graph) and length of 
seizures (in seconds; lower graph) of the recorded mice. Each color 
represents one mouse: green, vehicle-injected mouse; red and purple: 
PF-4708671(75 mg/kg)-treated mice. Treatment was administered at the 
moment indicated by the arrow, i.e, the day following the first night of 
seizures. (Preliminary data.) 
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Figure 23. PCR for Tsc1 in the Tsc1-GFAP mice under different 
conditions. Numbers code for brainstem tissue of adult mice: 1, 4 
tamoxifen injections; 2, 8 tamoxifen injections. Letters code for samples 
from a 4 weeks old mouse injected 8 times with tamoxifen: a, brainstem; 
b, cortex; c, hippocampus; d, cerebellum. A weak deletion band is only 
observed in the brainstem and hippocampus of 4 weeks old mice 
injected 8 times with tamoxifen. f: floxed band; -: deletion band 
70 
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Abstract 
 
Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder, 
resulting from inactivating mutations in either Tsc1 or Tsc2 genes. It is 
characterized by multisystemic benign tumors throughout the body, including 
the brain, together with neurological abnormalities such as epilepsy, autism and 
mental retardation (Han and Sahin, 2011; Orlova and Crino, 2010). 
The TSC1/2 protein complex has been found to play a crucial role in the 
regulation of cell growth and proliferation via the mTORC1 pathway. In the 
central nervous system this complex is also responsible for orchestrating finely 
tuned systems that have distinctive roles under different conditions; such as 
dendritic arborisation or axonal outgrowth and targeting (Orlova and Crino, 
2010). 
Given that 80 to 90% of all patients develop epileptic seizures (Han and 
Sahin, 2011), epileptogenesis is probably the most devastating and 
therapeutically challenging manifestation of TSC. Therefore, a rational 
preventive strategy is the targeting of the mTORC1 pathway, for its known 
contribution to epileptogenesis through protein synthesis and synaptic plasticity 
(Wong, 2010). 
Our lab has previously shown that global Tsc1 deletion in adult mice 
(using the CreER/loxP recombination system) results in epilepsy due to 
mTORC1 hyperactivation (Abs et al., in press). 
In order to further dissect the molecular mechanisms underlying 
epileptogenesis in TSC, we now induce Tsc1 deletion in adult mice, in a brain 
type cell-specific manner: using the Tsc1f/f αCaMKII-erT2-cre mouse model. 
These mice develop lethal epilepsy a few days after gene deletion onset 
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(assessed by EEG measurements). This epilepsy is accompanied by mTORC1 
hyperactivation (assessed by western blotting and immunohistochemistry) and 
no obvious brain pathology (immunohistochemistry). 
Moreover, this mouse model is hereby used to test possible treatments for 
epilepsy in TSC. We use different treatment options, such as dual mTOR 
inhibitors and a S6K inhibitor (contributing also to the understanding of 
epileptogenesis in these mice). 
Together with other cell-specific Tsc1 inducible KO mouse models, this 
project allows us to investigate the contribution of different types of brain cells to 
epilepsy (particularly in TSC). It will also help unraveling the molecular changes 
caused by acute mTORC1 hyperactivation (after all the developmental stages 
have taken place) that induce epileptogenesis. In addition, we are able to test 
novel treatment options for epilepsy in our mouse model. 
This project and the use of complementary mouse models are of great 
importance to both the scientific and medical fields, since they aim at a better 
understanding of epilepsy in TSC and the investigation of possible treatments. 
 
 
Keywords: TSC | Epilepsy | mTORC1 | Treatment 
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Resumo 
 
O Complexo Esclerose Tuberosa (TSC) é uma doença autossómica 
dominante, resultante de mutações inativantes em qualquer um dos genes 
Tsc1 ou Tsc2. A doença é caracterizada por tumores benignos espalhados pelo 
corpo, incluindo no cérebro, juntamente com anomalias neurológicas tais como: 
epilepsia, autismo e atraso mental (Han and Sahin, 2011; Orlova and Crino, 
2010). 
O complexo proteico TSC1/2 desempenha um papel crucial na regulação 
do crescimento e proliferação celular através da via mTORC1. No SNC este 
complexo também é responsável por orquestrar sistemas finos com papéis 
distintos sob diferentes condições como arborização dendrítica ou crescimento 
e orientação axonal (Orlova and Crino, 2010). 
Tendo em conta que 80 a 90% de todos os pacientes desenvolvem 
convulsões epilépticas (Han and Sahin, 2011), a epileptogénese é 
provavelmente a manifestação mais devastadora e terapeuticamente a mais 
desafiante em TSC. Uma estratégia preventiva racional tem como objectivo a 
modulação da via mTORC1, pela sua conhecida contribuição na 
epileptogénese através da síntese proteica e plasticidade sináptica (Wong, 
2010). 
O nosso laboratório demonstrou anteriormente que a eliminação global de 
Tsc1 em ratinhos apenas na idade adulta (usando o sistema de recombinação 
CreER/loxP) resulta no desenvolvimento de epilepsia devido à hiperactivação 
da via mTORC1 (Abs et al., in press). 
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De forma a dissecar os mecanismos moleculares subjacentes à 
epileptogénese em TSC, induzimos agora a eliminação de Tsc1 em ratinhos 
apenas na idade adulta, mas apenas em células específicas do cérebro: o 
modelo Tsc1f/f αCaMKII-erT2-cre. Estes ratinhos desenvolvem epilepsia letal 
logo após o início da deleção do gene (comprovado por meio de medições de 
EEG). Esta epilepsia é acompanhada por hiperativação da via mTORC1 
(verificado por western blotting e imunohistoquímica) e é livre de patologia 
cerebral (imunohistoquímica). 
Além disso, este modelo de ratinho será aqui usado para testar possíveis 
tratamentos para a epilepsia em TSC. Temos testado diferentes opções de 
tratamento tais como: inibidores duais de mTOR e um inibidor da S6K 
(contribuindo também para a compreensão da epileptogénese nestes ratinhos). 
Juntamente com outros modelos de ratinho passíveis de sofrerem 
eliminação induzida de Tsc1, este projecto permite-nos investigar a 
contribuição de diferentes tipos celulares para a epilepsia (particularmente em 
TSC). Este protejo também nos ajudará a desvendar as alterações moleculares 
causadas pela hiperactivação aguda da via mTORC1 (após todas as fases de 
desenvolvimento terem ocorrido) que induzem epileptogénese. Além disso, 
poderemos testar novas opções terapêuticas para epilepsia com este mesmo 
modelo. 
Este projecto juntamente com o uso de modelos complementares de 
ratinho são de grande importância para ambos os domínios: científicos e 
médicos, uma vez que visam uma melhor compreensão da epilepsia em TSC e 
investigação de tratamentos emergentes. 
Palavras-chave: TSC | Epilepsia | mTORC1 | Tratamento 
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Chapter 1 
 
 
 Introduction 
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Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder 
due to heterozygous inactivating mutations of either Tsc1 or Tsc2 tumor 
suppressor genes causing the development of benign tumors, epilepsy and 
cognitive deficits (Crino et al., 2006). 
The prognosis of the patients depends on the severity of the symptoms 
and is very variable, from doing well and living long productive lives, to suffering 
from serious disabilities and dying from kidney failure, brain tumor or status 
epilepticus (Crino et al., 2010). 
 
1.1 Molecular Mechanisms underlying TSC 
The encoded proteins of the Tsc1 and Tsc2 genes are, respectively, TSC1 
or hamartin and TSC2 or tuberin (see Figure 1). Together, they build up a 
complex where hamartin stabilizes and regulates tuberin, which then directly 
downregulates Rheb (Ras homologue enriched in brain) through its GAP 
(GTPase-activating protein) activity. Rheb, in its activated form (GTP-bound), is 
able to promote mTORC1 (mammalian or mechanistic target of rapamycin 
complex 1) catalytic activity in an amino acid availability-dependent manner 
(Huang and Manning, 2008). 
The mTORC1 is roughly composed by mTOR, the rapamycin-sensitive 
positive regulator RAPTOR (regulatory-associated protein of mTOR) and the 
negative regulator DEPTOR (DEP domain-containing mTOR-interacting 
protein). It controls several pathways that determine the mass or size of the cell, 
and it is also involved in axon guidance and temporal regulation of cell growth 
through protein translation (Huang and Manning, 2008). As shown in Figure 1, 
mTORC1 has three main downstream targets, addressed next: 
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1. mTORC1 phosphorylates the S6K1 (ribosomal S6 kinase 1) on Thr389, 
thereby activating it. In turn, S6K1 phosphorylates and activates S6 (40S 
ribosomal S6 protein) on Ser235/6, enhancing translation of mRNAs (Huang 
and Manning, 2008). 
2. Phosphorylation of 4EBP (eukaryotic translation initiation factor 4E-
binding protein) by mTORC1 stimulates cap-dependent translation of mRNAs 
that encode for proteins associated with the proliferative response and the 
transition from G1 to S phase in the cell cycle, critical for oncogenesis 
(Tsukiyama-Kohara et al., 2001). 
3. mTORC1 also has a direct negative influence on autophagy (very 
important for energy homeostasis and essential for normal development), 
inhibiting its classical initiators Ulk1 and Atg13 (autophagy-related protein 13). 
Autophagy levels are low in Tsc2 null cells and this deregulation may probably 
contribute to the neurologic manifestations of TSC (McMahon et al., 2012). 
mTOR can also associate with rapamycin-insensitive Rictor (rapamycin-
insensitive companion of mTOR), building up mTORC2 and being affected by 
rapamycin only under longer exposure times (Huang and Manning, 2008). 
mTORC2 signals to the actin cytoskeleton, controlling its polarity and thereby 
determining the shape of the cell. Akt (Protein kinase B) is activated by 
phosphorylation at Ser473 by mTORC2, in a PI3K (Phosphoinositide 3 kinase) 
dependent manner, promoting cell survival, growth and proliferation, as well as 
angiogenesis (Tavazoie et al., 2005). 
mTORC1 and 2 regulate each other: mTORC2’s signaling to Akt is a 
positive regulator of mTORC1. In turn, mTORC1 hyperactivation negatively 
modulates Akt through phosphorylated S6K mediated feedback loop (see 
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Figure 1). Although the involvement of mTORC2 in TSC is not entirely 
understood, there is some evidence of mTORC1 hyperactivation and reduced 
mTORC2 signaling (Tavazoie et al., 2005). 
In summary, the TSC1/2 complex is a key regulator of the mTORC1 
signaling pathway, serving as a hub for receiving a wide variety of cellular 
upstream signals (from growth factors or nutrients to inflammatory and stress 
signals), playing a major role in controlling protein synthesis, cell growth and 
proliferation, synaptic plasticity and axon specification and guidance (see 
scheme in Figure 1). 
 
 
Figure 1. Summarized scheme of the signaling pathway in TSC. In 
this disorder, the lack of a functional TSC1/2 complex leads to 
mTORC1 hyperactivation, culminating in uncontrolled cell growth and 
proliferation, as well as aberrant synapses. 
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1.2 TSC Patients and Mouse Models 
Several different TSC mouse models (with genetic engineered deletion of 
either Tsc1 or Tsc2 genes) were generated, aiming a better understanding of 
the different manifestations of the patients. In order to better understand how 
these models are comparable to TSC patients, I will hereupon discuss them 
side-by-side. 
TSC is the second most common hereditary neurocutaneous tumor 
syndrome, characterized by the development of tumors throughout the body, 
such as in skin, kidneys, lung and heart. Accordingly, TSC mouse models with 
heterozygous mutations in either Tsc1/2 genes also progressively develop 
peripheral tumors while aging, but no brain pathology (Onda et al., 1999). 
The brain of the patients is as well very affected in this disorder, with the 
development of giant cell astrocytomas, cortical tubers (focal malformations 
composed by giant cells with disrupted migration) and subependymal nodules. 
These may enhance and enlarge over time, becoming subependymal giant cell 
astrocytomas (SEGAs), potentially inducing obstructive hydrocephalus and 
death (Crino et al., 2006). Analysis of brain tissue from TSC patients has further 
taught us that there is unbalanced excitatory versus inhibitory signaling in 
tubers (Wang et al., 2007). Furthermore, changes in the levels of Glutamate 
and GABA receptors subunits, growth factors, as well as in ion channels (also 
involved in familial forms of epilepsy) were found and are summarized in 
Table I. 
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Table I. Molecular changes found in tuberal tissue from TSC patients 
AMPA- 
related 
↑ GluR1, 4 (↑ Ca2+ permeability) b, c 
↓ GluR2 and 3 b, c 
NMDA-
related 
↑ ↓ NR2A (↓ Mg2+ sensitivity) b, c 
↑ NR2B, 2C, 2D, 3A a, c 
GABAR-
related 
↓ GABAA R α1 (benzodiazepine insensitivity and GABA-
mediated excitation) c 
Ion 
channels 
KCNQ2/3 d 
↑ NKCC1 (deregulation Cl- transporter) c 
↓ KCC2 c 
Others 
↓ BDNF (immature transcription pattern) c 
Synapsin in dysplastic neurons (↑ network excitability) b 
Legend: a (White et al., 2001); b (Talos et al., 2008); c (Talos et al., 2012) and d (Scott 
and Holmes, 2012) 
 
The majority of the patients also show neurological and neuropsychiatric 
manifestations such as epilepsy, intellectual disability and autism spectrum 
disorders. Heterozygous TSC mouse models present cognitive deficits in the 
Morris water maze and contextual fear conditioning (Ehninger et al., 2008; 
Ehninger and Silva, 2011; Goorden et al., 2007); social deficits in social 
approach and nest building tests (Goorden et al., 2007; Sato et al., 2012) and 
anxiety with increased ultrasonic vocalizations between mother and pup 
(Ehninger and Silva, 2011; Young et al., 2010). Altogether, heterozygous TSC 
mouse models provided information concerning the tumors, cognition 
impairments and even autistic-like features. However, they did not allow the 
study of epilepsy, which is the most common neurological manifestation in TSC 
Epileptogenesis and Treatment Options in a TSC Epilepsy Mouse Model 
22 
(affecting almost 90% of the patients) and probably also the most challenging 
and very incapacitating, since it often presents itself in a severe and intractable 
form, being resistant to available pharmacological intervention (Thiele, 2004). 
Besides TSC-related, mTORC1 hyperactivation (following a seizure) was 
observed in several other models of epilepsy, such as in the kainate model 
(Wong 2010) or pentylenetetrazole-induced model (Zhang 2012). 
Until recently, the neurologic manifestations were directly associated with 
the brain pathology. However, there are now descriptions of patients suffering 
from seizures in the absence of brain tumors or following tuberectomy (Major et 
al., 2009; Orlova and Crino, 2010). Moreover, heterozygous mouse models 
show no brain pathology, suggesting that both alleles have to be silenced in the 
brain for the pathology and seizures to fully develop (Goorden et al., 2007). 
Homozygous deletion of either Tsc1 or Tsc2 genes, both in humans and 
mice, is embryonically lethal, due to disrupted neuroepithelial growth 
(Kwiatkowski et al., 2002). Interestingly, tumor tissue from the patients shows 
loss of heterozygosity (LOH) (Crino et al., 2010), strengthening the hypothesis 
that homozygous deletion in mice, if possible, should allow further studying of 
the disease. 
As a consequence, conditional mouse models were generated using cell-
specific cre expression and Cre-Lox recombination, allowing the generation of 
TSC mouse models with homozygous deletion of either Tsc1 or Tsc2 genes in 
specific cell types. 
As expected due to the cell-specific homozygous KO, some of these 
mouse models show progressive severe electroencephalographic seizures. 
Moreover, brain pathology was observed in some models, with giant and 
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ectopic cells, impaired migration and aberrational spine formation. Molecular 
analysis of conditional mouse models results in the most various conclusions, 
from changes in ion channels to glutamate receptor subunits shifts (following 
what has been found in human tissue). These findings are summarized in 
Table II. 
 
 
Table II. Summary of the Tsc1/2 conditional mouse models of TSC 
Cell Specificity Behavior Brain pathology 
Molecular 
analysis 
GFAP a-d 
(Radial-glia) 
• Epilepsy 
• Premature death 
↑ # astrocytes 
↑ Brain size 
• Neural 
disorganization 
↓ Kir channel  
↓ Glt1 
↓ GLAST 
↓ Connexin43 
Synapsin I e 
(Post-mitotic 
neurons at E13) 
↓ Development 
• Epilepsy 
• Premature death 
↓ Myelination 
• Aberrant neurons 
↑ pS6 
Nestin f 
(Neuroprogenitor 
cells during early 
brain development) 
↑ Brain size 
↓ Mother-pup 
interaction 
• Premature death 
(Not investigated) 
↓ TSC2 
↓ pAkt 
↑ pS6 
Emx1 g, h 
(Neuroepithelium 
stem cells at E10) 
• Epilepsy 
• Premature death 
↑ Neuronal cell size 
↓ Myelination 
• Abnormal migration 
↓ TSC2 
↓ pAkt 
↑ pS6 
↑ pErk 
↑ pSTAT3 
αCaMKII i 
(Excitatory neurons 
of the forebrain) 
• Epilepsy 
• Premature death 
(Not investigated) 
↑ pS6 
↑ pUlk 
Dlx5/6 j 
(GABAergic 
interneurons) 
↓ Growth 
• Decreased 
seizure threshold 
• Premature death 
↑ # GABA neurons 
• Impaired migration 
↑ pS6 
Epileptogenesis and Treatment Options in a TSC Epilepsy Mouse Model 
24 
PCP2 k or L7 l 
(Purkinje cells in 
cerebellum) 
↓ Motor skills 
↓ Social interaction 
↑ Anxiety 
↑ Grooming 
↓ # Purkinje cells 
↑ Cell size 
↑ Spine density  
• Abnormal axonal 
collaterals 
↑ pS6 
Legend: a (Uhlmann et al., 2002); b (Wong et al., 2003); c (Jansen et al., 2005); d (Way 
et al., 2009); e (Meikle et al., 2007); f (Anderl et al., 2011); g (Magri et al., 2011); h 
(Carson et al., 2012); i (McMahon et al., 2012); j (Fu et al., 2012); k (Reith et al., 2011) 
and l (Tsai et al., 2012). 
 
 
1.3 TSC Therapeutic Options 
Drugs targeting mTORC1 have been helpful in further investigating the 
disease and helping TSC patients. 
Rapamycin (the most widely described mTOR inhibitor) promotes 
RAPTOR dissociation, therefore down regulating the mTORC1 signaling 
pathway. This drug has been extensively studied in vitro, in animal models and 
even in TSC patients (clinical trials). In general terms, rapamycin is able to 
inhibit cell growth, proliferation and survival, therefore reducing hallmark 
processes of cancer (Seto, 2012). It has been used extensively in clinical trials 
of TSC patients not only for the tumors, but also for epilepsy and cognition. 
However, rapamycin’s strong immunosuppressant effect in some patients is a 
major problem (Bissler et al., 2008); so other mTOR inhibitors were generated. 
Advances in cancer therapeutics led to the development of ATP-
competitive mTOR inhibitors (also called second generation of mTOR 
inhibitors). These small molecules compete with ATP in the catalytic site of 
mTOR and down regulate its signaling pathway, therefore blocking the 
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feedback activation of PI3K/Akt signaling. Although this dual action might be of 
great interest for cancer (Wander et al., 2011), its value for TSC is still 
uncertain, and more drugs should be developed and tested in preclinical trials. 
Epilepsy in TSC is often refractory, meaning that it is resistant to several 
available therapies. However, there are some fairly successful cases to report. 
The ketogenic diet, used for years to treat epilepsy in children (including TSC-
related), is now described to act through down regulation of the mTOR pathway 
(McDaniel et al., 2011; Yamada, 2008). Also the anticonvulsives Vigabatrin, 
Lamotrigine and Clobazam seem to be effective in the treatment of epilepsy and 
infantile spasms in TSC; however, all these options carry dangerous side-
effects (Kessler et al., 2011; Wild et al., 2007), prompting for the discovery of 
novel options. 
Downstream proteins of the mTOR pathway should also be considered as 
potential therapeutic targets, since they will probably represent fewer side-
effects. One good example is the emergent S6K1 inhibitor PF-4708671, shown 
to strongly downregulate the readout for mTORC1 hyperactivation (pS6) (Di et 
al., 2012). 
 
 
1.4 Open questions in TSC 
From what was said, it becomes clear that a lot of questions remain to be 
answered in the study of TSC. 
The molecular mechanisms underlying the neurological manifestations are 
only partially understood. Therefore, this is one of the most important scientific 
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questions. Then again, research should also be focused on the patients, thus 
the discovery and testing of treatment options is mandatory. 
TSC mouse models are liable of being used in order to address both 
questions. Conditional mouse models allowed us to study epilepsy, but with 
limitations, because constitutive cre expression does not allow the study of the 
gene function in later stages of development (compensatory mechanisms occur 
during development, therefore masking the gene’s function). 
Therefore, inducible Cre recombination mouse models, experimentally 
controlled by tamoxifen administration, may be the answer. In this case, a 
modified version of Cre recombinase is fused to a mutated human estrogen 
receptor (ER), allowing the temporal control of Cre-mediated recombination 
(Feil et al., 1997; Metzger and Chambon, 2001). Peripheral tamoxifen 
administration (a synthetic ER ligand) induces the nuclear import of Cre-ER and 
the site-specific recombination of loxP-flanked target genes. In other words, 
these mice are born with an intact gene and normal protein expression, and 
exclusively upon peripheral tamoxifen administration the recombination takes 
place and they undergo Tsc1 biallelic deletion in a specific cell type (Figure 2). 
As a consequence, using inducible Cre makes the subsequent mouse breeding 
process simpler, because the mice do not suffer from developmental 
complications. 
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Figure 2. Initially (1), the Tsc1 gene is flanked by loxP sites and the 
cre is fused to a mutated estrogen receptor (ER) in the cytosol (the 
grey “pacman”). Tamoxifen administration (2), a potent ligand of the 
ER, induces the translocation of the ER-cre complex to the nucleus 
(3), where the cre recombinase recombines the loxP sites, resulting 
in Tsc1 gene deletion. If tamoxifen is not administered, or the mouse 
does not express the cre recombinase, the mouse remains similar to 
WT, i.e, Tsc1+/+. 
 
In these models, it will be very important to test if the cre recombinase is 
activated only upon tamoxifen administration, i.e., if it is not leaky. Also, optimal 
conditions to achieve maximal deletion rates with minimum tamoxifen 
administration must be found: tamoxifen dose and route of administration, age, 
gender and genetic background of the mice are probably variants to take into 
account. 
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Following these ideas, our lab previously crossed a Tsc1f/f mouse line with 
a cag-ert-cre mouse line, resulting in the Tsc1f/f–cag-ert-cre (henceforward 
referred to as Tsc1-cag) mouse model. This is a global inducible Tsc1 KO 
mouse model that may undergo Tsc1 deletion in all cells of the body upon 
tamoxifen administration during adulthood. Therefore, this mouse suffers acute 
mTORC1 hyperactivation, with no developmental complications. We reported 
that this mouse develops epilepsy and suffers premature death, with no obvious 
brain pathology, only a few days after gene deletion onset in adulthood (Abs et 
al., in press). In line with emerging evidence in the literature (showing increased 
mTORC1 in acquired epilepsy and the antiepileptogenic properties of mTOR 
inhibitors (McDaniel and Wong, 2011)) we concluded that mTORC1 has a direct 
signaling role in epilepsy. However, further investigation of the molecular 
mechanisms underlying the epilepsy in this mouse model (Tsc1-cag) was not 
possible, due to the shortened lifespan, so complementary mouse models are 
required. 
 
 
1.5 Aim of the study 
To further investigate the role of mTORC1 hyperactivation in TSC-related 
epilepsy, we now crossed the original Tsc1f/f mouse line with inducible cre lines 
(again, the cre recombinase is fused to a tamoxifen-sensitive estrogen receptor 
ERT2) driven by different brain cells-specific promoters. That way, we have now 
three different mouse models available that are able to undergo acute biallelic 
loss of Tsc1 in adulthood in a cell-specific manner: Tsc1f/f-αCaMKII-erT2-cre, 
Tsc1f/f-GFAP-erT2-cre and Tsc1
f/f-GAD2-erT2-cre. 
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The Tsc1f/f-αCaMKII-erT2-cre mouse (henceforward referred to as Tsc1-
αCaMKII) may suffer Tsc1 deletion upon tamoxifen administration in αCaMKII-
positive cells, which roughly comprises the pyramidal neurons of the forebrain 
(cortex and hippocampus), key brain structures in epileptogenesis, but also 
Purkinje cells in the cerebellum. This mouse will give insight on the αCaMKII 
cell-dependent mechanism contributing to epileptogenesis, disregarding of their 
role during development. 
The second mouse model, Tsc1f/f-GFAP-erT2-cre (Tsc1-GFAP), can suffer 
Tsc1 deletion in GFAP-positive cells, i.e., mature astrocytes. 
Third, the inhibitory neuron contribution to epileptogenesis will be 
addressed by inducing Tsc1 deletion in these cells, through tamoxifen 
administration in Tsc1f/f-GAD2-erT2-cre (Tsc1-GAD2) mice. 
We want to study epilepsy and, hopefully, further dissect the molecular 
mechanisms of epileptogenesis in each mouse model; assessing the different 
networks contribution to this devastating neurologic manifestation. We propose 
to address epilepsy using EEG recordings, and molecular and 
electrophysiological techniques to investigate the mechanisms underlying 
epileptogenesis in these mice. 
Moreover, by collaborating closely with small drug discovery companies, 
we also aim to test novel therapeutic options, therefore providing mechanistic 
data for the use of original drugs targeting different partners of the mTORC1 
molecular pathway. 
Overall, this project will investigate the contribution of different cell types to 
epilepsy (particularly in TSC) by acute mTORC1 upregulation and unraveling 
the molecular changes caused by mTORC1 hyperactivation that induce 
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epileptogenesis. In addition, we are able to test novel treatment options for 
epilepsy in our mouse model, providing novel information concerning these 
drugs’ action. 
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Chapter 2 
 
 
 Materials and Methods 
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2.1 Mice generation and breeding 
Tsc1f/f mice (Kwiatkowski et al., 2002) obtained from the Jackson 
Laboratory were crossed with transgenic mice carrying the cre-gene under the 
αCaMKII promoter (Erdmann et al., 2007) or GFAP promoter (Hirrlinger et al., 
2006). From these crossings, Tsc1f/f αCaMKII-erT2-cre mice (Tsc1-aCaMKII) 
and Tsc1f/f GFAP-erT2-cre mice (Tsc1-GFAP) were obtained, respectively. From 
the litters, only homozygous (f/f) mice were used, both carrying the cre gene 
(cre+, mutants) and not carrying it (cre-, control littermates). 
The mice were kept in IVC (individually ventilated cages) until adulthood 
and then collected to mouse experimental stables. Animals were kept in a 12-
hour light/dark cycle with ad libitum access to food and water. Genotyping of the 
mice short after birth (toe) and after death (ear) was made by specialized 
technicians using the following primers 5’-GTCACGACCGTAGGAGAAGC-3’, 
‘5’-GAATCAACCCCACAGAGCAT-3’ and 5’-AGGAGGCCTCTTCTGCTACC-3’ 
for Tsc1; 5’-GGTTCTCCGTTTGCACTCAGGA-3’, 5’-
CTGCATGCACGGGACAGCTCT-3’ and 5’-GCTTGCAGGTACAGGAGGTAGT-
3’ for the cre in the Tsc1-aCaMKII mice; and 5’-
CCTGGAAAATGCTTCTGTCCG-3’ and 5’-CAGGGTGTTATAAGCAATCCC-3’ 
for the cre in Tsc1-GFAP. 
For electroencephalography (EEG) recordings, western blot analysis and 
immunohistochemistry, independent groups of mice were used (numbers 
specified throughout the text). All animal experiments were approved by the 
Local Animal Experimentation Ethical Committee, in accordance with 
Institutional Animal Care and Use Committee guidelines. The experimenter 
remained blind to the genotype during data collection and initial analysis. 
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2.2 EEG surgical procedure 
Adult Tsc1-αCaMKII mice were deeply anesthetized with isoflurane 
(~1.5%) and injected with Rimadyl (Pfizer 1 µl/g body weight). Stainless steel 
screws (0.5 mm diameter) were used as EEG electrodes (lowered 1-1.5 mm 
below the skull to touch the dura mater). These were placed both on left and 
right sides above motor cortex (approximately 1.0 mm with reference to Bregma 
and midline), sensory cortex (approximately 2.0 mm with reference to Bregma 
and midline) and cerebellar cortex (approximately 1.0 mm with reference to 
midline). Before implantation, each screw was soldered to a soft insulated 
copper wire and, the other end of the wire to a pin (the screw to be used on the 
right side of the cerebellar cortex was soldered to two wires with two pins, being 
one the ground). All wires were connected to one common 7-pin connector 
compatible with the logging device and the whole structure was covered with 
dental cement (Kemdent, Swindon, UK) in a way suitable with the carrying of 
the apparatus. At the end of surgery, mice received 150 µl of morphine and 
were afterwards kept single caged (in a 12-hour light/dark cycle and ad libitum 
access to food and water). Figure 3 shows a scheme of the EEG surgical 
procedure. 
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Figure 3. The EEG surgical procedure takes place with the mouse 
deeply anesthetized (1). An incision is made in the skin and fascia 
overlying the skull (2). Stainless steel screws (a) are used as EEG 
electrodes (3) and implanted in the skull at the approximate 
coordinates shown in b. In the end, the other end of the electrodes is 
plugged in a connector (highlighted in orange) and covered with 
dental cement (4). Scheme in (b) is adapted from George Paxinos 
and Keith Franklin: The Mouse Brain in Stereotaxic Coordinates, 
Academic Press, 2001. 
 
 
2.3 EEG measurements 
Shortly before the start of the subsequent dark phase of the day, a 
wireless EEG recorder data logger (NewBehavior AG, Zurich, Switzerland), 
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hereupon called neurologger, was connected to the mice and 16 hours 
recordings were obtained every day. EEG analysis was made by scoring 
number and duration of seizures for all recordings. 
 
 
2.4 Tamoxifen administration 
Tamoxifen (Sigma) was dissolved in sunflower oil in a concentration of 
20 mg/ml by vortex and sonication. To induce Tsc1 gene deletion, Tsc1-
αCaMKII adult mice (at least 8 weeks old) were given 4 intraperitoneal 
injections of 0.1 mg/g of body weight of the tamoxifen emulsion. 
 
 
2.5 Immunohistochemistry 
After deep anesthesia with 0.15 ml Pentobarbital, mice were perfused with 
4% paraformaldehyde; the brains were post-fixed for 2 h and left overnight in a 
30% sucrose solution. The brains were sagittally sliced in 40 µm thick slices 
using a cryotome and transferred into 0.05 M Phosphate Buffer (PB). Free 
floating slices were rinsed in Phosphate Buffer Saline (PBS), blocked in a PBS 
solution with 10% normal horse serum (NHS) and 0.5% Triton X-100 and 
incubated with primary antibody in a PBS solution with 2% NHS and 0.5% 
Triton X-100, overnight. After rinsing, the incubation with the secondary 
antibody (Jackson Immunoresearch Europe Ltd, 1:200) took place for 1-2 h 
(depending on antibody). In the end, slices were rinsed several times in PB 
0.05 M and mounted on glass with chromaluin. For immunohistochemistry, 
slices were also blocked for blood as first step in a PBS solution with 10% H2O2 
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and after the secondary antibody the slices went through the standard avidin-
biotin-immunoperoxidase complex method (ABC, Vector Laboratories) with 
diaminobenzidine (DAB) as the chromogen. 
αCaMKII stainings require an antibody solution with 5% Triton X-100, 2% 
NHS and 1% BSA in PBS, without blocking step. 
To assess gross brain morphology sections were mounted on glass and 
stained with thionin. Visual examination of pS6 stained slices was done in order 
to identify enlarged cells- included when they were 4 times larger than 
neighboring cells. 
DAB and thionin stained slices were observed under an Olympus 
microscope (type CX 41), while fluorescent stained slices were observed under 
a Zeiss LSM700 confocal microscope. 
Primary antibodies against αCaMKII (Novus Biologicals NB100-1983, 
1:500 for fluorescence), Parvalbumin (SWANT, 1:9000) and pS6S235/6 (CST 
#2211, 1:1000) were used.  
 
 
2.6 Western blot 
Lysates were prepared after quick dissection of the different brain areas 
(hippocampus, cortex and cerebellum) followed by homogenization in lysis 
buffer (0.1 M Tris HCl pH 6.8, 2.5% SDS for total lysates, 10 mM Hepes pH 7.4 
with 0.32 M sucrose, 1 mM NaHCO3 and 1 mM MgCl2 for synaptosomes) 
containing protease and phosphatase inhibitor cocktails (Sigma-Aldrich). 
The concentration of all lysates was adjusted to 1 mg/ml and 15 µl were 
loaded on a 4-12% gradient SDS-PAGE, running at 150 V for 1.5 h, followed by 
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a semi-dry transfer for 1.5 h at 15 V, or a wet transfer for 40 min at 100 V 
(depending on the molecular weight of the proteins of interest). The blot was 
incubated with the primary antibodies with 2% milk in Tris-buffered saline-
Tween 20 0.1% (TBST) overnight, after blocking with 5% milk. After washing 
with TBST, the incubation with the secondary antibody took place for 1 h 
(Odyssey, 1:5000). The Li-Cor Odyssey fluorescence imaging system was used 
for the membrane development and the LiCor Odyssey 2.1 software was used 
for quantification. Primary antibodies against TSC1 (#4906, 1:1000), TSC2 
(#3612, 1:1000), pS6S235/6 (#2211, 1:2000), S6 (#2217, 1:3000), pAktS473 
(#4060, 1:2000), Akt (#2920, 1:8000), NR1 (#5704, 1:1000), NR2A (#4205, 
1:1000), NR2B (#5580, 1:1000), GluR1 (#8850, 1:1000) all from Cell Signaling 
Technology, Danvers, MA and GABAAR α1 (Milipore #06-868, 1:1000) and actin 
(MAB1501R; Chemicon, Billerica, MA, 1:20000) were used. All samples were 
run in at least two independent experiments. 
 
 
2.7 Drug preparation 
The AZD8055 dual mTOR inhibitor, a kind gift from Griffin Discoveries, 
was aliquoted in DMSO in a concentration of 50 mg/ml and kept at -80oC. For 
the testing of the compound in wild-type mice, fresh syringes were prepared 
after vortexing of the aliquots and administration of 10 mg/kg. 
The novel dual mTOR inhibitor GD124, also a kind gift from Griffin 
Discoveries, was aliquoted in DMSO in a solution of 10 mg/ml and kept at -
80oC. For the testing of the compound in wild-type mice, fresh syringes were 
prepared after vortexing of the aliquots and administration of 15 mg/kg. 
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The S6K1 inhibitor PF-4708671 (Pfizer) was kept as a powder at room 
temperature. For the treatment experiment in our mutant mice, fresh syringes 
were prepared with vigorous vortex after sonication of the drug in a solution of 
5% Tween-80 (v/v) in saline and the mice were injected with 75 mg/kg. 
 
 
2.8 Statistical analysis 
GraphPad Prism data analysis software (San Diego, CA) was used for 
statistical analysis. Mean values and SEM are shown as error bars and p<0.05 
was considered significant (being identified in the graphs by an asterisk (*)). 
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3.1 Characterization of the Tsc1-αCaMKII mouse model 
To investigate whether acute biallelic loss of Tsc1 in a cell-specific manner 
is sufficient to induce epilepsy in adult mice and further dissect the molecular 
mechanisms of epileptogenesis, we generated inducible Tsc1 KO mice using 
the cre/LoxP gene-targeting strategy with the cre fused to a tamoxifen-sensitive 
mutated estrogen receptor. Firstly, we used the cre-line driven by the αCaMKII 
promoter, originating Tsc1-αCaMKII mice (Figure 4). For this study, cre+ and 
cre- littermates are used. 
 
 
Figure 4. Tsc1f/f mice were crossed with the cre line carrying the 
αCaMKII promoter until the Tsc1f/f-αCaMKII-erT2-cre construct, with 
cre+ and cre- littermates, was obtained. 
 
This mouse model, upon peripheral administration of tamoxifen, 
undergoes biallelic Tsc1 deletion in αCaMKII-positive cells, which are widely 
expressed in pyramidal excitatory neurons of the forebrain, not being present in 
any peripheral organ. Injection of Tsc1-αCaMKII cre+ mice with tamoxifen 
induces translocation of the creERT2 protein to the nucleus to drive 
recombination of the floxed Tsc1 allele only in αCaMKII-positive cells, resulting 
in cell-specific Tsc1 null mice. On the other hand, tamoxifen injection to Tsc1-
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αCaMKII cre- mice does not result in recombination; since the cre is not present 
(see Figure 2). To confirm the specificity of this mouse model and its cre line, 
DNA was isolated of different brain areas and peripheral tissue from these mice 
after 4 tamoxifen injections. A PCR was made to assess Tsc1 gene deletion 
(primers used described in chapter 2, Figure 5). As expected, we observed 
partial Tsc1 deletion in both cortex and hippocampus (where αCaMKII is widely 
expressed), with no deletion in cerebellum (due to the lower number of 
αCaMKII-positive cells) or liver (a very reliable negative control, due to the 
brain-specificity of this cre-line) of cre+ Tsc1-αCaMKII mice. Vehicle-injected 
mutant mice (cre+) show no recombination, proving that the cre line is not 
leaky. Control mice (cre-) are also injected with tamoxifen throughout the study, 
to control for any adverse effect of the drug (accordingly, these mice show no 
recombination). 
 
 
Figure 5. PCR for Tsc1 using different brain areas and liver of Tsc1-
αCaMKII mice. Only cre+ tamoxifen injected mice show partial 
deletion in cortex and hippocampus. f: floxed band; -: deletion band  
 
To confirm this result on the protein level, as well as validating the Tsc1 
deletion effect on mTORC1 hyperactivation (using pS6/S6 levels as readout), 
we addressed TSC1 and pS6 levels in these brain areas by western blotting 
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(Figure 6). TSC1 levels dropped in hippocampus, cortex and cerebellum, 
however, only the first two show mTORC1 hyperactivation (increased pS6/S6 
levels), so we believe the cerebellum will not play a major role in the phenotype 
of our mouse model. Henceforward, the brain areas of our focus will be the 
cortex and hippocampus. 
 
 
  
 
 
Figure 6. TSC1 and pS6/S6 levels in αCaMKII-positive brain regions 
of Tsc1-αCaMKII mice that underwent Tsc1 deletion: hippocampus 
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(Hc), cortex (Ct) and cerebellum (Cb). All protein levels were 
normalized to the respective brain area in control mice (1 unit, dark 
line). All brain areas show decreased TSC1 levels, following Tsc1 
gene deletion. However, only hippocampus and cortex show 
mTORC1 hyperactivation (increased pS6/S6 levels). n=2 per group 
(preliminary data). 
 
 
As widely described in literature, pS6 increased levels are used as 
readouts for mTORC1 hyperactivation. In the case of our mouse model, 
mTORC1 hyperactivation is due to Tsc1 deletion. Since no TSC1 antibody is 
available to be used for immunohistochemistry, we will use pS6 stainings as 
readout for Tsc1 deletion (Figure 7). In accordance with our previous result, pS6 
increased levels are only observed in the hippocampus and cortex of mutant 
mice, with no differences in cerebellum  
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Figure 7. Sagital sections (5 x magnification) of a control (left) and a 
mutant Tsc1-αCaMKII mouse brain stained with an antibody against 
pS6. pS6-positive cells are highly present in cortex and hippocampus 
of the mutant Tsc1-αCaMKII mouse, while no differences are found in 
cerebellum. n=4 per group. 
 
 
To investigate whether the Tsc1 deletion was specific for αCaMKII-positive 
cells, we performed co-stainings for pS6 (hereby used as readout for Tsc1 
deletion) and αCaMKII (cell-type that is undergoing Tsc1 deletion). In our 
mouse model, pS6-positive cells show high co-localization with αCaMKII-
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positive cells (Figure 8), but not with Parvalbumin-positive cells (PV is a marker 
for GABAergic interneurons) (Figure 9). 
 
 
 
Figure 8. pS6-positive cells (red) highly co-localize with αCaMKII-
positive cells (green) in cortex (A, 10x; B, 20x) and hippocampus (C, 
5x, D, 20x dentate gyrus, E, 20x CA3 region) of Tsc1-αCaMKII mice. 
n=5. 
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Figure 9. pS6-positive cells (red) do not co-localize with PV-positive 
cells (green) in cortex (A, 10x; B, 20x) and hippocampus (C, 5x, D, 
20x dentate gyrus, E, 20x CA3 region) of Tsc1-αCaMKII mice. 
 
At this point, we are able to claim that our mouse model is able to undergo 
Tsc1 gene deletion in αCaMKII-positive cells when injected 4 times with 
tamoxifen in adulthood. This induced Tsc1 deletion results in mTORC1 
hyperactivation in hippocampus and cortex, crucial brain structures of the 
forebrain involved in epilepsy. 
Following the conditional deletion in this same cell type (see Table II, 
(McMahon et al., 2012)) and the severe epilepsy developed by our global 
inducible mouse model (Tsc1-cag; (Abs et al., in press)); we hypothesize that 
this mouse will develop epilepsy and allow the study of mTORC1-dependent 
epileptogenesis. 
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3.2 αCaMKII-driven acute deletion of Tsc1 is sufficient to induce lethal 
epilepsy in adult mice 
To assess epilepsy in these mice, surface electrodes were implanted in 
the brain through the EEG surgical procedure (explained in detail in chapter 2, 
Figure 3). EEG recordings were performed using the neurologger device 
(protocol in Figure 10, examples of recordings and device in Figure 11). 
 
 
Figure 10. Adopted protocol to assess epilepsy in Tsc1-αCaMKII 
mice through EEG recordings. After the EEG surgical procedure the 
mice are given a minimum of two days of rest. Then, two vehicle 
injections are administered and baseline measurements are acquired. 
After one day of rest, gene deletion is induced by tamoxifen 
administration and EEG measurements are acquired every night. 
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Figure 11. Examples of the observed types of recordings (A, 
baseline measurement; B, increased activity; C, seizure; D, lethal 
seizure) and the wireless neurologger device.  
 
Here we show that αCaMKII-driven Tsc1 deletion in adulthood led to the 
development of spontaneous or handling-induced seizures. Epilepsy onset 
occurred as soon as 9 days after gene deletion onset (Figure 12) and was 
lethal, with the cre+ mice having a median survival of 15 days after the first 
tamoxifen injection, i.e., after gene deletion onset (Figure 13). Epilepsy in these 
mice is tonic-clonic, followed by a period of loss of upright posture and 
generalized clonus of all limbs 
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Figure 12. The epilepsy onset of tamoxifen-injected cre+ mice varies 
between 9 and 12 days after the first tamoxifen injection in adulthood. 
Tamoxifen-injected cre- mice don’t show epilepsy. n=10. 
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Figure 13. Lifespan of tamoxifen-injected cre+ mice varies between 
12 and 16 days after the first tamoxifen injection in adulthood. 
Tamoxifen-injected cre- mice don’t show decreased lifespan. n=4. 
 
The number and length of all recorded seizures are presented in Figure 
14. These mice show, in average, 2 seizures of 30 seconds per 16 h of 
recording and the number of seizures seems to decrease with the epilepsy 
development over time. 
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Figure 14. Number (per 16h of recording; upper graph) and length of 
seizures (in seconds; lower graph) of the recorded mice. Each color 
represents one mouse. n=3. 
 
As a conclusion, Tsc1-αCaMKII mice develop epilepsy only 9 days after 
gene deletion onset and die a few days after. In contrast to the Tsc1-cag mice 
(Abs et al., in press), the Tsc1-αCaMKII mice always die after a seizure, 
whereas the first do not (their death is most probably related to kidney failure). 
Therefore, a brain-specific Tsc1 deletion, in excitatory neurons of the forebrain, 
reveals itself as a more suitable tool to study mTORC1-dependent epilepsy 
(and epilepsy in general). Moreover, the cell-specific KO shows less variability 
in epilepsy onset than the global KO (Tsc1-cag mice develop epilepsy 2 to 
9 days after gene deletion onset). Yet, epilepsy appears to be equally severe, 
leaving only a small window to study the molecular mechanisms underlying 
epileptogenesis. 
In summary, Tsc1-αCaMKII mice develop epilepsy around 10 days after 
gene deletion onset and die approximately 15 days after, following a seizure. 
Epileptogenesis and Treatment Options in a TSC Epilepsy Mouse Model 
54 
The number of seizures per period of EEG recording seems to decrease over 
time, probably due to acute Tsc1 deletion followed by some compensatory 
mechanisms taking place afterwards. Moreover, it prompts us to hypothesize 
that molecular changes take place in a time-dependent manner. 
These results allow us to use day 8 as a pre-epileptic time-point and day 
13 as an epileptic state of the mice, and address the molecular changes in 
these two moments. 
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3.3 αCaMKII-driven acute deletion of Tsc1 in adulthood is accompanied by 
mTORC1 hyperactivation 
To address mTORC1 hyperactivation in these mice, we measured TSC1 
and TSC2 levels, as well as pS6 (readout for mTORC1) and pAkt levels 
(readout for mTORC2) in hippocampal tissue (Figure 15), 8 and 13 days after 
gene deletion onset. Accordingly, TSC1 protein levels decrease in a time-
dependent manner (due to gene deletion) and TSC2 levels follow the first, as 
previously described (Benvenuto et al., 2000). mTORC1 hyperactivation is 
evident by the 3 fold increase in pS6 levels in mutant mice and mTORC2 down 
regulation, as assessed by decreased pAkt levels in mutant mice. 
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Figure 15. TSC1, TSC2, pS6/S6 and pAkt/Akt levels in control mice 
(c; cre- tamoxifen-injected) and mutant mice (tamoxifen injected cre+) 
at day 8 (8; pre-epileptic state) and day 13 (13; epileptic state). 
Significant differences are shown by * (p=0.01, 1-way ANOVA), n=4 
per group. 
 
 
3.3 Ongoing work 
As we could observe, after gene deletion onset TSC1 levels drop in a 
time-dependent manner, followed by mTORC1 hyperactivation (pS6/S6 levels 
increase). However, mTORC1 hyperactivation is also triggered by epilepsy, 
including non-TSC related. For example, the kainate-induced epilepsy model in 
rats shows increased levels of pS6 in several different time points (Wong, 
2010).  
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To distinguish between mTORC1 hyperactivation due to Tsc1 loss and 
the hyperactivation caused by the seizures themselves we will perform the 
following additional experiments. 
Firstly, we will address mTORC1 hyperactivation at the exact moment 
where half the animals show epilepsy and the other half does not. That way, we 
can observe in the group without epilepsy the mTORC1 hyperactivation only 
due to reduced TSC1 protein levels. The group with epilepsy should have 
similar amounts of TSC1 left at that time point, but probably shows a further 
increased mTORC1 activity due to the presence of seizures. To test this we will 
stain brains of tamoxifen injected cre+ mutant mice that, at the same time-point 
after the initiation of gene deletion, show or do not show epilepsy. 
Secondly, we aim to discriminate between the effect of chronic and acute 
epilepsy. For that, we will sacrifice a group of animals, again at day 13 (mice 
already suffering from epilepsy), shortly after inducing a seizure by gentle 
fixation. That way, all the mice will have been through an epileptic state shortly 
before our molecular analysis, possibly showing differential levels of mTORC1 
hyperactivation (similar to the non-TSC related models of epilepsy, where 
increased pS6 is observed a couple of hours after seizure induction) and 
therefore allowing us to further dissect its role in epilepsy. Moreover, this 
approach will, hopefully, allow us to amplify the molecular changes that follow 
seizures, further adding understanding to the molecular mechanisms following 
epileptogenesis. 
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Altogether, this data will allow us to draw more conclusions regarding the 
role of mTORC1 hyperactivation in epilepsy, as well as provide some clues 
concerning the molecular changes underlying epileptogenesis (addressed in 
detail in the following subchapter). 
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3.4 Epileptogenesis in Tsc1-αCaMKII mice 
To investigate the molecular changes potentially leading to 
epileptogenesis, we decided to explore the molecular changes found in tuberal 
tissue from patients (see Table I), also shown is some conditional mouse 
models (see Table II). Again we used three different groups of mice: the control 
mice, that do not undergo Tsc1 deletion even though they are tamoxifen-
injected; mice sacrificed at day 8, i.e., that do not show epilepsy, but may 
demonstrate already some molecular changes that underlie epilepsy 
development and mice at day 13, that by now show epilepsy for at least 2 days. 
To assess changes in the amount of AMPA and NMDA receptors subunits, 
firstly in hippocampal total lysates (Figure 16), we run western blots with 
antibodies against NR1, NR2A and NR2B (NMDAR subunits) and GluR1 
(AMPAR subunit). 
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Figure 16. NR1, NR2A and NR2B NMDA subunits and GluR1 AMPA 
subunit levels in hippocampal total lysates of control (c) and mutant 
mice at day 8 (8) or day 13 (13). n=4 per group, no significant 
differences were found (preliminary data). 
 
 
Unfortunately, no differences between the groups were found, so we 
questioned ourselves whether it is not the total amount of subunits hat it is 
changed, but the location of these subunits. In other words, we speculated 
whether changes in these receptors subunits might be due to trafficking, and 
not protein amount. To address this question, we isolated synaptosomes of 
cortical tissue from mice at the same time-points and investigated NMDAR and 
GABAR subunits levels (Figure 17). Again, no differences were found. 
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Figure 17. NR2B, NR2A and NR1 NMDA subunits and GABAARα1 
subunit levels in cortical synaptosomes of control (c) and mutant mice 
at day 8 (8) and day 13 (13). n=4 per group, no significant differences 
were found (preliminary data). 
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3.4 Ongoing work 
In order to investigate the synaptic mechanisms that may be underlying 
epilepsy in these mice, possibly through mTORC1 signaling, we will focus on 
exploring the molecular changes found in the patients’ brain tissue (see Table 
I). At the moment, we are still measuring protein levels of AMPAR and NMDAR 
subunits in the synaptosomes preparations and GABAAR subunits in the total 
lysates. Changes in synapsin, an important protein that regulates 
neurotransmitter release at synapses (shown to be increased in brain tissue 
from TSC patients - see Table I), will also be investigated. Lysates with 
enriched post synaptic density (PSD) proteins are also being addressed for all 
these receptors subunits. That way, we will measure protein amount in different 
cell compartments, obtaining indirect evidence of trafficking of these receptors. 
Altogether, we are confident that this data will allow us to draw some 
conclusions concerning the network-dependent molecular changes in these 
mice. In other words, we might be able to understand mTORC1 hyperactivation 
involvement in amount or location of different Glutamate and GABA receptors 
subunits that may be underlying epileptogenesis in our mouse model. 
Moreover, pinpointing one or another subunit will have a major impact in how 
we look at these synapses from the electrophysiological point of view (in the 
future electrophysiology experiments). 
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3.5 No obvious brain pathology in Tsc1-αCaMKII mice 
In line with the observations in the Tsc1-cag mouse, adult deletion of 
Tsc1 only in αCaMKII-positive cells does not result in changes in gross brain 
morphology as assessed by thionin stainings (Figure 18). 
 
 
 
  
Figure 18 No differences in gross brain morphology are observed in 
the hippocampus of Tsc1-αCaMKII mice (control on the left, mutant 
on the right). (All perfused brains were screened and no changes 
were found.) 
 
 
 
Also, it does not lead to the development of giant cells (widely described 
as developmental brain pathology in some conditional mouse models, see 
Table II), as assessed by screening for pS6 positive cells that are 4 times bigger 
than the surrounding cells in the cortex of epileptic mice (Figure 19). 
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Figure 19 No pS6-stained giant cells are found in the cortex of Tsc1-
αCaMKII epileptic mice (10 x magnification on the left, 40 x 
magnification on the right). 
 
 
Although experiments are still ongoing, it is clear that this mouse model 
is a valuable tool to study epileptogenesis in TSC, independent of brain 
pathology. Therefore, we asked ourselves if we would be able to treat this 
epilepsy (by extending lifespan or reduce seizure burden), while providing initial 
mechanistic data for novel drugs. 
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3.6 Testing novel therapeutic options for TSC 
In order to investigate the therapeutic value of novel dual mTOR inhibitors 
in TSC, we initially validated these drugs ability to cross the blood brain barrier 
and to have an effect on mTORC1 and mTORC2 signaling in the brain of wild-
type (WT) mice. 
First, we tested the AZD8055 compound, which was described as an 
antitumor drug, strongly down regulating mTORC1 (decreasing pS6/S6 and 
p4EBP1/4EBP1 and inducing autophagy) as well as mTORC2 (pAkt/Akt levels) 
signaling in xenographs of mouse models of cancer (Chresta et al., 2010). We 
injected mice two times with either AZD8055 (10 mg/kg) or vehicle (DMSO), 
with an inter-injection interval of 16 h. The mice were sacrificed 3 h after the last 
injection. 10 mg/kg of AZD8055 were able to decrease both mTORC1 and 
mTORC2 readouts (pS6/S6 and pAkt/Akt, respectively) in the brain of WT mice 
(Figure 20). 
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Figure 20. AZD8055 (10 mg/kg) is able to downregulate mTORC1 
(pS6/S6 levels) and mTORC2 (pAkt/Akt levels) in the hippocampus of 
WT mice. n=2 per group (preliminary data). 
 
Secondly, we tested the novel compound GD124. This drug was 
designed to be a potent dual mTOR inhibitor and shown to inhibit mTORC1 
activity (pS6 levels) in an in vitro essay. For this experiment, we injected WT 
mice with either GD124 (15 mg/kg) or vehicle (DMSO) and sacrificed them 4 
and 8 h after a single injection (to also investigate the drug’s half-life). However, 
we failed to find any effect on pS6 or pAkt (Figure 21). 
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Figure 21. The effect of GD124 on mTORC1 and mTORC2 in the 
hippocampus of WT mice is inconclusive. n=2 per group (preliminary 
data). 
 
In addition, we tested the S6K1 inhibitor, PF-4708671; previously used in 
a mouse model of cardiac infarction and able to reduce pS6 levels in this organ 
(Di et al., 2012). 
Following validation of this drug’s effect in decreasing S6K activity by a 
collaborating group, we decided to test this drug as a therapeutic approach in 
our mouse model. We wonder if inhibiting only the S6K downstream arm of the 
mTORC1 pathway, especially because it is also involved in the crosstalk with 
mTORC2 (see Figure 1), would be enough for the treatment of epilepsy. For 
that, we started with a pilot study with only 3 mutant mice. We induced Tsc1 
deletion in adulthood (as previously) and we assessed epilepsy onset: these 3 
mice showed epilepsy onset either at day 10 or 11, fitting our previous findings 
(see Figure 12). During the day of the subsequent EEG recording that showed 
epileptic seizures, we administered the S6K inhibitor in a concentration of 75 
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mg/kg in two of the mice and only vehicle in the third mouse (as a control). 
Unfortunately, this pilot study was not very successful, since the two treated 
mice died 1 and 2 days after treatment onset. We could speculate that the used 
concentration was too low, or that the treatment was initiated too late (after 
epilepsy onset) or even that, in fact, inhibiting only this arm of the mTORC1 
pathway is not enough to treat epilepsy. 
In Figure 22, we show number of seizures per 16 h of recording and length 
of seizures of these 3 mice, being the vehicle-injected mouse the one in green. 
We can see that the two mice used for the treatment had a high number of 
seizures during the first night (roughly, 7 and 10 compared to 3), as well as a 
higher average of length of seizures, so that might suggest that the seizure 
burden was too high to be treated with this drug. 
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Figure 22. Number (per 16h of recording; upper graph) and length of 
seizures (in seconds; lower graph) of the recorded mice. Each color 
represents one mouse: green, vehicle-injected mouse; red and 
purple: PF-4708671(75 mg/kg)-treated mice. Treatment was 
administered at the moment indicated by the arrow, i.e, the day 
following the first night of seizures. (Preliminary data.) 
 
 
 
3.6 Ongoing work 
At the moment, we are further testing these drugs in their ability as 
antiepileptic treatments in our mouse model, i.e., their ability to alleviate seizure 
severity or reduce epilepsy progression as well as increase lifespan. 
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3.7 Preliminary findings in the Tsc1-GFAP mouse model 
As explained in chapter 1, our overall interest is investigating the 
molecular mechanisms underlying epilepsy in TSC and, for that, we generated 
different mouse models. The next one to be addressed is the Tsc1f/f-GFAP-erT2-
cre, in which tamoxifen administration results in Tsc1 deletion in GFAP-positive 
cells. 
As a first approach, we injected adult mice with 4 and 8 tamoxifen 
injections. Due to the failure in inducing cre-recombination with this treatment 
scheme, we then injected 4 weeks old mice for 8 consecutive days (as 
described in (Hirrlinger et al., 2006)). However we again failed to achieve Tsc1 
gene deletion (Figure 23). 
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Figure 23. PCR for Tsc1 in the Tsc1-GFAP mice under different 
conditions. Numbers code for brainstem tissue of adult mice: 1, 4 
tamoxifen injections; 2, 8 tamoxifen injections. Letters code for 
samples from a 4 weeks old mouse injected 8 times with tamoxifen: 
a, brainstem; b, cortex; c, hippocampus; d, cerebellum. A weak 
deletion band is only observed in the brainstem and hippocampus of 
4 weeks old mice injected 8 times with tamoxifen. f: floxed band; -: 
deletion band 
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Due to these difficulties, we are now setting up a new breeding of these 
mice, in which we will try different approaches, from earlier tamoxifen-injection, 
to changes in the used dose. 
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 Discussion 
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TSC is a complex disease with an underlying molecular pathway up until 
now not fully understood. Moreover, targeted treatments have been under 
investigation but none has been successful for all aspects of this multifaceted 
disease (they either have an effect on the tumors, or partially control the 
seizures, etc). Therefore, research in TSC is very challenging, but mandatory 
for the patients. 
Epilepsy is probably the most challenging neurologic manifestation of 
TSC and, so far, it has only been possible of being observed in conditional 
mouse models (where biallelic Tsc1 or Tsc2 deletion occurs only in a specific 
subset of cells). As a result, our lab previously studied a global inducible Tsc1 
KO, that could undergo Tsc1 deletion only in adulthood: Tsc1-cag-esr-cre (Abs 
et al., in press). Similar to developmental Tsc1 deletion, deletion in adulthood is 
lethal, probably due to kidney failure (which is a major cause of death also 
among the patients), but only after epilepsy development. However, the time 
window to study epileptogenesis was too narrow in this mouse model, 
prompting the generation of cell-specific inducible mouse models. 
We now crossed the Tsc1f/f mouse line with the transgenic cre-lines 
driven by the αCaMKII, GFAP or GAD2 promoters, in order to obtain Tsc1-
αCaMKII, Tsc1-GFAP and Tsc1-GAD2 mouse models, respectively. These 
mice may undergo biallelic Tsc1 deletion in excitatory neurons, astrocytes or 
inhibitory neurons, only upon tamoxifen administration. In other words, we now 
have available three TSC mouse models that will, most likely, not show 
peripheral complications (due to the brain-specific gene deletion), and may 
allow the study of the mTORC1 hyperactivation role in epilepsy, probably in a 
more focused way (no developmental or peripheral complications will mask the 
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possible epilepsy development and the molecular or electrophysiological 
changes that accompanied it). 
In this thesis we make use of the first mouse model, Tsc1-αCaMKII, to 
investigate the molecular mechanisms underlying epileptogenesis and the 
ability of novel drugs to treat epilepsy in TSC. 
In accordance to the high αCaMKII expression throughout the forebrain, 
a key structure in epileptogenesis, the Tsc1-αCaMKII mouse develops severe 
and lethal epilepsy in just 9 to 12 days after gene deletion onset, with mTORC1 
hyperactivation and no developmental brain pathology. In line with the brain-
specific driven deletion, no peripheral abnormalities were observed; and, as far 
as our investigation went, epilepsy was the only symptom of these mice. 
Therefore, we just provided to the scientific community a very useful mTORC1-
dependent epilepsy mouse model that will allow us to study the molecular 
mechanisms underlying epileptogenesis. Moreover, novel drugs targeting 
mTORC1/2 were here tested in their ability to target the brain, as well as an 
S6K inhibitor, that is now being tested as an antiepileptic drug in our mouse 
model. Altogether, this project represents a major first step in investigating 
mTORC1 hyperactivation-dependent epileptogenesis, a feature also present in 
non-TSC related forms of epilepsy. 
 
Gene deletion magnitude is dependent on tamoxifen amount. Here we 
report that four tamoxifen injections are enough to induce mTORC1 
hyperactivation in the majority of αCaMKII-positive cells, due to Tsc1 gene 
deletion. Further analysis of this statement will be done by crossing our mouse 
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model with a Tomato- reporter line, therefore allowing us to investigate the 
activated cre in a cell-specific manner. 
Tsc1 gene deletion is followed by mTORC1 hyperactivation. In order to 
correctly investigate mTORC1 hyperactivation, the three signaling arms should 
be analyzed: pS6, p4EBP1 and pUlk (see Figure 1). 
First, in our mouse model, phosphorylated S6 was shown to be 
increased in a time-dependent manner after gene deletion and possibly in a 
differential manner between epileptic and non-epileptic mice at the same time-
point (ongoing work). 
Secondly, p4EBP1 would represent a step further in understanding the 
cap-translational mechanisms, shown to be rapamycin treatment insensitive 
(Thoreen and Sabatini, 2009) and most likely playing a major role in 
epileptogenesis in our mouse model. However, we failed to assess its levels in 
brain (due to the low levels together with inadequate antibody condition). The 
p4EBP2 isoform is brain-specific, possibly overcoming the protein availably 
issue, but previous reports also document difficulties in assessing this protein 
levels (Bidinosti et al., 2010). The third option would be to look at the different 
isoforms of the 4EBP1/2 proteins, although no differences were found in the 
Tsc1-cag mouse model. Nevertheless, one of these options will most certainly 
be used in the future to try and understand how this arm of the mTORC1 
signaling is involved in epilepsy in our mouse model. 
Third, the autophagy arm, suggested to contribute to epileptogenesis 
(McMahon et al., 2012), was also not addressed in our mouse model, but we 
aim to do it in the close future. 
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Tsc1 gene deletion is also followed by decreased levels of pAkt. 
Although this decrease is widely accepted as meaning mTORC2 down 
regulation, some topics are still under discussion. Therefore, other readouts for 
mTORC2, such as pNDRG1, should also be addressed. That way, it will be 
possible to distinguish between mTORC2 down regulation or direct pAkt 
inhibition due to S6K feedback loop, representing also a step further in the 
understanding of the mTOR complexes crosstalk in TSC. We planned to 
address pNDRG1 in our mouse model in the short run. 
The still ongoing experiments concerning the epilepsy characterization 
will also shed light in some remaining questions, such as mTORC1 hyperactivity 
role in epilepsy. 
The epileptogenesis investigation is, without a doubt, the most important 
question in this project and further study on this topic will be addressed in a 
multidisciplinary way. 
First, further testing for changes in expression and localization of 
glutamate receptors subunits, as well as GABAR subunits and ion channels, 
also in other brain areas, will be taken care of, aiming to understand if brain 
tissue of this mouse model is comparable to the tubers from the patients. 
Secondly, as mentioned in the ongoing work of subchapter 3.4, the 
molecular investigation of the glutamate signaling in this mouse model will also 
serve as an indication of the questions to be addressed by electrophysiology 
experiments: the use of specific blockers will allow us to investigate changes in 
receptor expression, in addition to the usual questions, such as excitability, 
mEPSCs, mIPSCs, etc; contributing to the understanding of the excitability 
pattern of the cell and its network connectivity. In addition, high deletion 
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efficiency is of major importance for electrophysiology experiments, where a 
homogenous cell population should be present. That way, the neuron is 
representative for the changes suffered by a pyramidal cell that went through 
complete Tsc1 loss, thereby reducing variability. 
Third, we need to understand what the molecular cause of death in these 
mice is. Differently from the global KO (Tsc1-cag), which dies from a peripheral 
complication, the mouse hereby investigated dies after a seizure. This 
phenomenon is widely known as status epilepticus (a major cause of death 
among TSC patients), and the molecular causes are still under investigation, 
but somehow meet the molecular changes found in tuberal tissue from patients: 
Glutamate and GABA receptors subunits. In other words, a lethal seizure 
happens probably due to a failure in the mechanisms that terminate seizures, 
such as persistent excitation and failed inhibition signaling. Therefore, dynamic 
changes in the receptors, instead of presence or trafficking of different subunits 
(as we address in subchapter 3.4), could be possibly happening, and 
complementary electrophysiological technical approaches should be 
considered. 
Epilepsy onset in our mouse model is less variable than in the global KO 
(Abs et al., in press). Speculations about this observation encourage us to 
pursuit these cell-specific mouse models, because they will, as hypothesized, 
allow the dissection of the different features of complex disorders into narrower 
and narrower windows and less interference factors. Therefore, for all of these 
questions, the three cell-specific Tsc1 mouse models that we have now in our 
hands could provide us with further insight into the network and cell-dependent 
mechanisms. 
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In contrast to the other cell-specific TSC mouse models, our inducible 
mouse model is free of developmental brain pathology and does not seem to 
show changes in overall brain morphology (no giant cells or gross brain 
morphology changes). This further strengthens the hypothesis that possibly 
tubers or tumors are not epileptogenic foci per se, but either the homozygous 
cells within them, that might somehow fail to maintain proper synaptic contact, 
membrane excitability or regular receptor trafficking; forming aberrant 
connections and network hyper excitability. Even tough, a closer look at cell 
morphology using, for example, the Gene gun approach that specifically stains 
isolated cells in a slice, would either show us different results or further strength 
the just-mentioned hypothesis. 
From the two dual mTOR inhibitors that we tested, AZD8055 and GD124, 
only the first seems to be able to downregulate both mTOR complexes 
(decreasing pS6 and pAkt levels) in the brain of WT mice. On the other hand, 
the novel GD124 compound’s ability to have an effect on mTOR complexes 1 
and 2 in the brain of WT mice seems inconclusive and we are now focused on 
further addressing this question e.g. by testing a higher dose and at different 
time points as well as additional testing in in vitro essays (a good collaboration 
with Mark Nellist from the Clinical Genetics Department). Moreover, these drugs 
will be further tested in our mouse model, i.e., in their ability of abolishing 
seizures and increase lifespan, as an antiepileptic treatment. Altogether, this 
investigation will help us understand how these drugs may or not be valuable in 
mTORC1-related epilepsy. 
The S6K inhibitor showed promising results in its ability of decreasing 
pS6/S6 levels in the brain of WT mice (unpublished data by Eric Klann group); 
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therefore, we tested it as an antiepileptic treatment for our mouse model. This 
pilot study revealed itself as a disappointment and the speculation can go to the 
most various justifications. Was the dose used not high enough? Did the 
treatment come too late? Is it just absurd to consider that inhibition of only one 
mTORC1 downstream pathway could be efficient in treating such severe 
epilepsy?... A new approach will be defined to try to use this drug as a 
treatment: a higher dose or administration before the seizure onset, is a 
possibility to consider. If evidenced that this drug does not work as an anti-
epileptic treatment, the S6K inhibitor also represents a major tool in 
understanding epileptogenesis in TSC by dissecting the role of the mTORC1-
S6K arm in epilepsy. 
During this project we were also able to have the first preliminary results 
concerning the second cell-specific mouse model: Tsc1f/f-GFAP. We attempted 
the induction of gene deletion by testing different protocols of tamoxifen 
administration, but the obtained deletion band does not seem to reach the 
published data on the original transgenic mouse (Hirrlinger et al., 2006). 
Therefore, optimal conditions to obtain gene deletion will have to be further 
tested, before using the model in e.g. behavioral experiments. Developmental 
deletion of Tsc1 in GFAP-positive cells was widely studied (see Table II) and it 
is consistent in resulting in epilepsy and brain pathology, so we are looking 
forward to investigate epilepsy and lifespan when Tsc1 is deleted only in mature 
astrocytes. Moreover, the phenotype of this mouse will give us further insight 
onto the cell-specific contribution to epileptogenesis in the patients. 
Soon, the third mouse model, Tsc1-GAD2, will be investigated and the 
same questions will be addressed: epilepsy, lifespan, molecular changes, etc. 
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We can already speculate that this deletion will not be enough to the 
development of epilepsy, since the developmental deletion of Tsc1 in inhibitory 
neurons (driven by the Dlx5/6 promoter, summarized in Table II) only results in 
decreased seizure threshold. However, a lot of questions are still to answer 
concerning the role of mTORC1 hyperactivation in inhibitory neurons. 
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Altogether, our results confirm that acute mTORC1 upregulation in only 
αCaMKII-positive neurons is sufficient to cause epilepsy, which confirms the 
major role of this cell-type in epileptogenesis in TSC, including in adulthood. 
Moreover, the cause of lethality in these mice is epilepsy, motivating us to 
investigate the molecular mechanisms underlying the source of death in this 
mouse model. 
The study of this mouse opens novel questions that will be soon 
addressed by using the complementary cell-specific mouse models (Tsc1-
GFAP and Tsc1-GAD2) and further studies in other systems. When the story is 
complete, the cell type (excitatory and inhibitory neurons as well as astrocytes) 
dependent molecular contribution to epileptogenesis in TSC will be drafted and, 
together with previous studies, a bigger picture of the cellular and molecular 
mechanisms, together with the network properties underlying epileptogenesis 
will be drawn. 
In conclusion, this project is the first step on a wide field that will most 
certainly help us understand epilepsy (not only TSC-related), contributing to the 
understanding and possibly helping to find therapeutic options for such dramatic 
neurologic manifestation that incapacitates half a million people worldwide. 
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